The global cell and gene therapy market size was valued at USD 27.38 billion in 2025 and is projected to grow from USD 33.85 billion in 2026 to USD 184.60 billion by 2034, registering a CAGR of 23.62% during the forecast period from 2026 to 2034. North America dominated the cell and gene therapy market with a market share of 46.8% in 2025.
Cell and gene therapy includes advanced medical treatments that modify or replace genes or use living cells to treat, prevent, or potentially cure diseases. These therapies are widely used for genetic disorders, certain cancers, and rare diseases by targeting the root cause of illness. Demand is growing due to rapid advances in biotechnology, increasing clinical research, and rising investments in personalized and regenerative medicine.
Download a Free Sample To learn more about this report,
Integration of AI in Cell and Gene Therapy Design
Cell and gene therapy market analysis shows that artificial intelligence is shifting therapy design from conventional trial-and-error approaches toward data-driven identification of therapeutic targets, gene sequences, and cell characteristics. AI models can analyze genomic and cellular datasets to identify promising targets and predict how engineered cells may behave, helping researchers refine candidates before laboratory testing. Recent AI applications in protein and gene sequence design demonstrate the potential to accelerate the development of engineered biological therapies.
Adoption of Off-the-Shelf Cell Therapies
Off-the-shelf cell therapies are transitioning treatment models from patient-specific cell manufacturing toward standardized products prepared from healthy donor cells. Allogeneic cells can be engineered, expanded, and stored in advance, which can reduce manufacturing time and allow treatment to be available without waiting for an individual patient's cells to be processed. Clinical development of allogeneic CAR-T therapies, including donor-derived products for cancer treatment, reflects this shift toward more readily available cell-based therapies.
Demand for Therapies for Rare and Life-Threatening Diseases and Expansion of Cell and Gene Therapy Manufacturing Capacity Drive Market
The limited treatment options for rare and life-threatening diseases create demand for cell and gene therapies that address specific genetic or cellular causes. Patients with conditions such as sickle cell disease and spinal muscular atrophy can benefit from therapies designed to provide long-lasting clinical effects. FDA-approved gene therapies such as Casgevy for sickle cell disease demonstrate the application of these approaches in serious disorders. Greater demand for treatments addressing significant unmet medical needs therefore supports the Cell and Gene Therapy Market.
The expanding clinical pipeline creates supply requirements for specialized facilities capable of producing cell therapies, viral vectors, and other advanced therapeutic materials. Additional manufacturing capacity can support clinical trials and commercial production while reducing dependence on limited processing facilities. Contract development and manufacturing organizations also provide specialized capabilities for viral-vector production and cell processing. Greater availability of dedicated manufacturing infrastructure therefore strengthens the supply of cell and gene therapies and supports market growth.
High Manufacturing Costs and Shortage of Specialized Expertise Restrain Market Expansion
High manufacturing and treatment costs arise from specialized vector production, cell processing, quality testing, personalized manufacturing, and complex clinical delivery requirements. These expenses increase the financial burden on therapy developers, healthcare providers, and patients, particularly for treatments that require individualized production. As a result, limited affordability and high development costs can slow adoption and restrict Cell and Gene Therapy Market growth.
A shortage of specialized manufacturing and clinical expertise limits the availability of professionals who can handle cell processing, gene modification, quality control, and therapy administration. This talent gap can constrain production capacity, increase training requirements, and make expansion into new treatment centers more difficult. Consequently, limited operational capacity can delay commercialization and restrict market adoption.
Expansion of Cell and Gene Therapies in Autoimmune Diseases and Adoption of Cell and Gene Therapies in Cardiovascular Disorders Offers Growth Opportunities
Biopharmaceutical companies, cell-therapy developers, and specialty healthcare providers can develop therapies for autoimmune conditions such as lupus and multiple sclerosis. Revenue avenues include investigational therapies, cell-processing services, and licensing partnerships. Companies such as Novartis, Bristol Myers Squibb, and Kyverna Therapeutics are developing cell-based approaches for autoimmune diseases.
Biopharmaceutical companies, gene-therapy developers, and cardiovascular centers can explore therapeutic approaches for heart failure, ischemic heart disease, and inherited cardiovascular conditions. Revenue opportunities include gene therapies, cell-based treatments, clinical development partnerships, and specialized treatment services. Companies such as AstraZeneca, Bayer, and Rocket Pharmaceuticals are involved in cardiovascular cell or gene therapy research.
Complex Manufacturing Scale-Up, Batch Consistency, and Long-Term Safety Monitoring Challenges
Cell and gene therapies require tightly controlled biological processes, and scaling production while maintaining consistent product quality remains difficult. Variations between batches can increase validation and quality-control requirements, making commercial-scale production more challenging.
Some therapies require extended monitoring to assess delayed adverse events, durability, and long-term treatment outcomes. These requirements can lengthen clinical development and increase post-treatment monitoring obligations, slowing the expansion of new therapies.
The CAR-T Cell Therapy segment accounted for a share of 22.4% in 2025 due to its established clinical use, strong therapeutic potential in blood cancers, and increasing adoption of personalized cancer treatments. The availability of approved CAR-T therapies for certain hematological malignancies further supports its dominant market position.
The allogeneic CAR-T segment is expected to grow at a CAGR of 23.62%, driven by its potential for off-the-shelf treatment, faster availability, and scalable manufacturing compared with patient-specific therapies. The cell therapy segment supports market growth through the use of living cells to repair, replace, or modify damaged tissues and treat serious diseases. The autologous CAR-T segment contributes through personalized therapies developed from a patient’s own T cells. The CAR-NK segment supports adoption through engineered natural killer cells designed for targeted cancer treatment. The B-Cell segment contributes through cell-based therapies targeting B-cell-related cancers and immune disorders. The others segment supports market growth through additional cell therapy approaches for specialized therapeutic applications. The gene therapy segment contributes through genetic modification to correct, replace, or regulate disease-causing genes. The viral segment supports adoption through viral vectors that efficiently deliver therapeutic genetic material into target cells. The AAV segment contributes through adeno-associated viral vectors used for targeted and long-lasting gene delivery. The ientiviral vectors segment supports market growth through efficient gene transfer and stable genetic modification of target cells. The others segment contributes through additional viral and non-viral vector technologies for gene delivery.
Request Customizationto receive a tailored report.
The oncology segment accounted for a share of 48.7% in 2025 due to the widespread use of cell and gene therapies for targeted cancer treatment, particularly in hematological malignancies and advanced solid tumors. The availability of approved therapies and continued clinical development in cancer treatment further supports its dominant market position.
The neurology segment is expected to grow at a CAGR of 21.12%, driven by the development of cell and gene therapies for neurological disorders and the need for targeted treatments for complex conditions. The dermatology segment supports market growth through cell and gene therapies for skin disorders, wound healing, and tissue regeneration. The musculoskeletal segment contributes through regenerative therapies for bone, cartilage, muscle, and joint conditions. The immunology segment supports adoption through therapies targeting immune-related disorders and immune system dysfunction. The others segment contributes through cell and gene therapy applications across additional therapeutic areas.
The biopharmaceutical & biotechnology companies segment accounted for a share of 49.5% in 2025 due to their extensive research capabilities, advanced manufacturing infrastructure, and strong focus on developing cell and gene therapies. Their established clinical development networks and access to specialized technologies further support their dominant market position.
The CDMOs/CMOs segment is expected to grow at a CAGR of 21.35%, driven by the increasing outsourcing of cell and gene therapy manufacturing, specialized production capabilities, and scalable manufacturing infrastructure. The pharmaceutical companies segment supports market growth through investments in cell and gene therapy development, clinical programs, and commercialization. The others segment contributes through research institutions, academic organizations, and specialized healthcare entities involved in therapy development and production.
Speak to an Analystto discuss market opportunities.
The North America Cell and Gene Therapy Market accounted for the largest regional share of 46.8% in 2025. Strong clinical research activity, advanced healthcare infrastructure, and increasing investment in cell and gene therapy development support the region’s leading position in the market.
The U.S. cell and gene therapy market is supported by projections of an average of 63.5 cumulative cell and gene therapy product-indication approvals and about 93,000 patients treated in the u.s. by 2030, according to a peer-reviewed analysis published in Drug Discovery Today. The Canada cell and gene therapy market is supported by a c$35.95 million federal investment to establish automated good manufacturing practice facilities for cell and gene therapy products in Ontario, with the project running through 2047 and expected to strengthen domestic cell-therapy supply chains.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific Cell and Gene Therapy Market is expected to grow at a CAGR of 21.48% during the forecast period, showcasing the fastest-growing regional market. Increasing clinical research, expanding biopharmaceutical manufacturing capabilities, and greater investment in advanced therapies are supporting market growth across the region. The Japan cell and gene therapy market is supported by Japan’s planned expansion of regenerative medicine, with the Ministry of Health, Labour and Welfare supporting gene-therapy commercialization through a dedicated 2026 program and reporting that two iPS-cell-based regenerative medicine products were moving toward conditional, time-limited approval in 2026.
The China cell and gene therapy market is supported by Shanghai’s policy framework, which targets faster development and commercialization of cell and gene therapies while encouraging clinical-grade viral-vector technologies and large-scale cell-culture processes. The South Korea cell and gene therapy market is supported by the government’s 2026–2030 advanced regenerative medicine plan, which expands treatment infrastructure, broadens cell-supply pathways, and strengthens research and commercialization support for advanced regenerative therapies. The india cell and gene therapy market is supported by the government’s target of expanding the country’s bioeconomy to $300 billion by 2030, while the bioe3 policy specifically identifies cell and gene therapy as a precision-biotherapeutics priority and promotes biomanufacturing hubs and biofoundries.
The Europe Cell and Gene Therapy Market accounted for a regional share of 27.4% in 2025. Strong research capabilities, supportive regulatory frameworks, and increasing investment in advanced therapies are supporting the adoption of cell and gene therapies across the region.
The U.K. cell and gene therapy market is supported by the UK government’s life sciences sector plan, which aims to position the country as the leading life sciences economy in Europe by 2030 and the third globally by 2035, alongside continued investment in advanced therapy research and manufacturing. The Germany cell and gene therapy market is supported by Germany’s national strategy for gene and cell therapy, which is designed to strengthen the full value chain from basic research through clinical development and improve the country’s capacity to develop and commercialize these therapies. The France cell and gene therapy market is supported by the government’s biotherapy and innovative therapy bioproduction strategy, which targets production of at least 5 new biomedicines, doubling sector employment from 10,000 to 20,000, and establishing France as a European leader in pharmaceutical bioproduction by 2030.
The Middle East & Africa Cell and Gene Therapy Market is expected to grow at a CAGR of 15.92% during the forecast period, showcasing the fastest-growing regional market. Increasing investment in advanced healthcare infrastructure, biotechnology research, and innovative treatment capabilities is supporting the adoption of cell and gene therapies across the region.
The UAE cell and gene therapy market is supported by the national genome strategy, a 10-year program through 2033 that aims to accelerate personalized and precision medicine for genetic and rare diseases, while Abu Dhabi’s helm cluster is expanding biotechnology, medical innovation, and pharmaceutical manufacturing capabilities. The Africa cell and gene therapy market is supported by the WHO’s 2026–2030 mrna technology transfer programme, which aims to help regional manufacturers scale commercially sustainable, GMP-grade production of mrna-based vaccines and therapeutics, alongside Africa’s 2025–2035 framework for strengthening local production of medicines and health technologies.
The cell and gene therapy market is moderately fragmented, with competition involving established pharmaceutical companies, biotechnology firms, specialized cell and gene therapy developers, contract development and manufacturing organizations, and emerging life sciences companies. The leading players in the Cell and Gene Therapy Market include Novartis, Gilead Sciences, Bristol Myers Squibb, Vertex Pharmaceuticals, and Bayer AG, collectively accounting for approximately 25–28% of the market.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Epigenetics Market Size, Share, Growth, Analysis, Report, 2034
Biobanking Market Size, Share, Growth, 2034
Cell Therapy Manufacturing Market Size, Share, Growth, 2034
Clinical Oncology Next Generation Sequencing Market Size, 2034
Autoimmune Disease Diagnostics Market Size, Share, Growth, 2034
Cannabis Testing Market Size, Share, Growth, Forecast, 2034
We are featured on:
sales@straitsresearch.com